Compare WVE & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | HTFL |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | Singapore | United States |
| Employees | 317 | 843 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 2.5B |
| IPO Year | 2015 | N/A |
| Metric | WVE | HTFL |
|---|---|---|
| Price | $5.68 | $30.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $29.81 | ★ $38.20 |
| AVG Volume (30 Days) | ★ 3.9M | 1.1M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | N/A | $27.66 |
| Revenue Next Year | $85.67 | $23.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.02 | $20.13 |
| 52 Week High | $21.73 | $41.22 |
| Indicator | WVE | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 52.83 |
| Support Level | $5.02 | $28.37 |
| Resistance Level | $7.65 | $32.69 |
| Average True Range (ATR) | 0.32 | 1.87 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 10.14 | 53.55 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.